Breast cancer risk modification in women with pathogenic variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2.
Breast cancer risk modification in women with pathogenic variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2. Cancer Res Commun. 2025 Apr 29.
PMID: 40298171
Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population.
Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population. Ann Oncol. 2025 Apr 25.
PMID: 40288678
GLP-1RA Use and Thyroid Cancer Risk.
GLP-1RA Use and Thyroid Cancer Risk. JAMA Otolaryngol Head Neck Surg. 2025 Mar 01; 151(3):243-252.
PMID: 39847346
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast. Clin Cancer Res. 2025 Jan 06; 31(1):130-138.
PMID: 39513960
Pathogenic variants in cancer susceptibility genes predispose to Ductal Carcinoma In situ of the breast.
Pathogenic variants in cancer susceptibility genes predispose to Ductal Carcinoma In situ of the breast. Clin Cancer Res. 2024 Nov 08.
PMID: 39513960
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach. Breast Cancer Res. 2024 Oct 29; 26(1):148.
PMID: 39472970
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer. J Oncol Pharm Pract. 2024 Oct 13; 10781552241289581.
PMID: 39397422
Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population.
Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population. medRxiv. 2024 Oct 12.
PMID: 39417132
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk.
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clin J Am Soc Nephrol. 2024 Oct 08.
PMID: 39729347
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.
Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Clin Diabetes. 2025; 43(1):59-70.
PMID: 39829688
View All Publications